Market Size of Preimplantation Genetic Testing Industry
Study Period | 2021 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 10.50 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Preimplantation Genetic Testing Market Analysis
The preimplantation genetic testing market studied was anticipated to grow with a CAGR of 10.5% during the forecast period.
During COVID-19, there was an increasing adoption of the preimplantation of genetic testing, which is expected to drive the market's growth. The NCBI article published in October 2021 mentioned preimplantation genetic testing and embryologist specialization provided safety and assisted reproduction process have not negatively impacted patients with a previous record of COVID-19 infection. However, according to another NCBI article published in September 2022, women with COVID-19 during Pregnancy might have a higher risk of obstetrical and neonatal complications. Such risk of pre-natal complications in the infected patients boosted the demand for preimplantation genetic testing during the pandemic. Thus, the COVID-19 pandemic has increased the market's growth, which is expected to follow the same traction during the forecast period of the study.
The primary factor attributing to the market's growth is a rising awareness among parents regarding advancements in diagnostics, with a massive volume of neonatal deaths due to complications during childbirth. The growing prevalence of congenital genetic diseases like Edwards syndrome and common pediatric respiratory disorders such as pneumonia and asthma has been observed in recent years. As per the NCBI article published in August 2021, the in-facility birth prevalence rate for congenital abnormalities in South Africa was 15.57 per 1,000 live births. Another NCBI published in September 2022 states that the live birth prevalence with Edwards syndrome in the UK ranges from 1 in 3600 to 1 in 10,000. These abnormalities occur almost exclusively in couples with hereditary disorders, which were observed to occur majorly in industrialized nations. Thus, increased demand for earlier diagnosis and government initiatives to control the healthcare burden will likely drive the preimplantation genetic testing market.
Additionally, the increasing product launches by various market players are expected to boost market growth over the forecast period. For instance, Eurofins Genoma launched the niPGT-A, a non-non-invasive, in September 2022. It is an embryo biopsy-free, preimplantation genetic aneuploidy screening test. It provides IVF centers with access to a highly accurate alternative to traditional PGT-A testing.
Thus, the factors such as the growing prevalence of congenital genetic diseases and increasing product launches are expected to contribute to the market's growth over the forecast period. However, the small size of the study population and ethical concerns, costly testing procedures, and unfavorable regulatory framework and challenges during the development stage may restrain the market's growth over the forecast period.
Preimplantation Genetic Testing Industry Segmentation
As per the scope of the report, preimplantation genetic testing is the genetic profiling of embryos employed before implantation in IVF workflow, and sometimes even of oocytes before fertilization for a successful pregnancy. These tests help make the right decision for couples at risk of hereditary disorders, whether to terminate the pregnancy or not, by detecting the presence of disease during gestation. These tests also benefit women in IVF cycles who faced miscarriages earlier or those who had the last pregnancy with an abnormality in chromosomes. The Preimplantation Genetic Testing Market is segmented by test type( Preimplantation Genetic Diagnosis, Preimplantation Genetic screening), products and services (instruments, reagents, and consumables, software and services), application (HLA Typing, IVF Prognosis, Aneuploidy Screening, and other applications), end user (hospitals and diagnostic labs, maternity centers, and fertility clinics and other end users), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value in (USD million) for the above segments.
By Test Type | |
Preimplantation Genetic Diagnosis (PGD) | |
Preimplantation Genetic Screening (PGS) |
By Product and Service | |
Instruments | |
Reagents and Consumables | |
Software and Services |
By Application | |
HLA Typing | |
IVF Prognosis | |
Aneuploidy Screening | |
Other Applications |
By End User | |
Hospitals and Diagnostic Labs | |
Maternity Centers and Fertility Clinics | |
Other End Users |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Preimplantation Genetic Testing Market Size Summary
The preimplantation genetic testing market is poised for significant growth, driven by increasing awareness among parents about advancements in diagnostics and the rising prevalence of congenital genetic diseases. The COVID-19 pandemic has further accelerated this growth, as it highlighted the importance of preimplantation genetic testing to mitigate prenatal complications in infected patients. The market is also benefiting from the growing demand for earlier diagnosis and government initiatives aimed at reducing healthcare burdens. The introduction of innovative products, such as non-invasive testing methods, is expected to enhance market expansion. However, challenges such as ethical concerns, high costs, and regulatory hurdles may pose constraints to market growth.
The IVF prognosis segment is anticipated to capture a substantial share of the preimplantation genetic testing market, fueled by the increasing number of IVF procedures and the rising incidence of infertility. North America is expected to lead the market, supported by a high prevalence of genetic disorders and active participation from key market players. The region's growth is further bolstered by partnerships and collaborations aimed at developing advanced genetic testing solutions. The competitive landscape is characterized by major players focusing on research and development, alongside strategic product launches, to maintain their market dominance.
Preimplantation Genetic Testing Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Burden of Genetic Diseases Like Patau Syndrome, Edwards Syndrome, and Down Syndrome
-
1.2.2 Increased Government Initiatives to Create Awareness and R&D Activities to Develop Advanced Diagnostic Devices
-
-
1.3 Market Restraints
-
1.3.1 Small Size of Study Population and Ethical Concerns
-
1.3.2 Highly Expensive Testing Procedures
-
1.3.3 Unfavorable Regulatory Framework and Challenges During Development Stage
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Test Type
-
2.1.1 Preimplantation Genetic Diagnosis (PGD)
-
2.1.2 Preimplantation Genetic Screening (PGS)
-
-
2.2 By Product and Service
-
2.2.1 Instruments
-
2.2.2 Reagents and Consumables
-
2.2.3 Software and Services
-
-
2.3 By Application
-
2.3.1 HLA Typing
-
2.3.2 IVF Prognosis
-
2.3.3 Aneuploidy Screening
-
2.3.4 Other Applications
-
-
2.4 By End User
-
2.4.1 Hospitals and Diagnostic Labs
-
2.4.2 Maternity Centers and Fertility Clinics
-
2.4.3 Other End Users
-
-
2.5 Geography
-
2.5.1 North America
-
2.5.1.1 United States
-
2.5.1.2 Canada
-
2.5.1.3 Mexico
-
-
2.5.2 Europe
-
2.5.2.1 Germany
-
2.5.2.2 United Kingdom
-
2.5.2.3 France
-
2.5.2.4 Italy
-
2.5.2.5 Spain
-
2.5.2.6 Rest of Europe
-
-
2.5.3 Asia-Pacific
-
2.5.3.1 China
-
2.5.3.2 Japan
-
2.5.3.3 India
-
2.5.3.4 Australia
-
2.5.3.5 South Korea
-
2.5.3.6 Rest of Asia-Pacific
-
-
2.5.4 Middle East and Africa
-
2.5.4.1 GCC
-
2.5.4.2 South Africa
-
2.5.4.3 Rest of Middle East and Africa
-
-
2.5.5 South America
-
2.5.5.1 Brazil
-
2.5.5.2 Argentina
-
2.5.5.3 Rest of South America
-
-
-
Preimplantation Genetic Testing Market Size FAQs
What is the current Preimplantation Genetic Testing Market size?
The Preimplantation Genetic Testing Market is projected to register a CAGR of 10.5% during the forecast period (2024-2029)
Who are the key players in Preimplantation Genetic Testing Market?
Illumina Inc, Thermo Fisher Scientific Inc, PerkinElmer Inc, Bioarray S L and Cooper Surgical are the major companies operating in the Preimplantation Genetic Testing Market.